###begin article-title 0
Epstein-Barr Virus Independent Dysregulation of UBP43 Expression Alters Interferon-Stimulated Gene Expression in Burkitt Lymphoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: IKR JTS. Performed the experiments: IKR JLH. Analyzed the data: IKR JLH JTS. Wrote the paper: IKR JTS.
###end p 1
###begin p 2
###xml 40 48 <span type="species:ncbi:9606">Children</span>
Current address: Shriner's Hospital for Children, Research Division, Portland, Oregon, United States of America
###end p 2
###begin p 3
###xml 539 547 539 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 644 651 644 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1434 1437 1434 1437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1429 1437 1429 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ubp43<sup>&#8722;/&#8722;</sup></italic>
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 20 23 <span type="species:ncbi:10376">EBV</span>
###xml 97 100 <span type="species:ncbi:10376">EBV</span>
###xml 253 256 <span type="species:ncbi:10376">EBV</span>
###xml 347 350 <span type="species:ncbi:10376">EBV</span>
###xml 583 586 <span type="species:ncbi:10376">EBV</span>
###xml 691 694 <span type="species:ncbi:10376">EBV</span>
###xml 794 797 <span type="species:ncbi:10376">EBV</span>
###xml 1438 1444 <span type="species:ncbi:10090">murine</span>
Epstein-Barr virus (EBV) persists as a life-long latent infection within memory B cells, but how EBV may circumvent the innate immune response within this virus reservoir is unclear. Recent studies suggest that the latency-associated non-coding RNAs of EBV may actually induce type I (antiviral) interferon production, raising the question of how EBV counters the negative consequences this is likely to have on viral persistence. We addressed this by examining the type I interferon response in Burkitt lymphoma (BL) cell lines, the only in vitro model of the restricted program of EBV latency-gene expression in persistently infected B cells in vivo. Importantly, we observed no effect of EBV on interferon alpha-induced signaling or evidence of type I interferon production, suggesting that EBV in this latent state is silent to the cell's innate antiviral surveillance. We did uncover, however, a defect in the negative feedback control of interferon signaling in a subpopulation of BL lines as was revealed by prolonged interferon-stimulated gene transcription consistent with sustained tyrosine phosphorylation on STAT1 and STAT2. This was due to inadequate induction of expression of the ubiquitin-specific protease UBP43, which removes the ubiquitin-like ISG15 polypeptide conjugated to proteins (ISGylation) in response to type I interferons. Results here are consistent with previous findings in genetically engineered Ubp43-/- murine cells that UBP43 down-regulates interferon signaling, independent of its ISG15 isopeptidase activity, by precluding the protein kinase JAK1 from the interferon receptor. This natural deficiency in UBP43 expression may therefore provide a useful model to further probe the biological roles of UBP43 and ISGylation.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 120 123 120 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYC</italic>
###xml 212 215 212 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Boxer1">[1]</xref>
###xml 944 949 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BARTs</italic>
###xml 1008 1011 1008 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Cai1">[2]</xref>
###xml 1012 1015 1012 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Pfeffer1">[4]</xref>
###xml 307 325 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 327 330 <span type="species:ncbi:10376">EBV</span>
###xml 371 374 <span type="species:ncbi:10376">EBV</span>
###xml 446 449 <span type="species:ncbi:10376">EBV</span>
###xml 477 480 <span type="species:ncbi:10376">EBV</span>
###xml 551 554 <span type="species:ncbi:10376">EBV</span>
###xml 804 807 <span type="species:ncbi:10376">EBV</span>
###xml 997 1000 <span type="species:ncbi:10376">EBV</span>
###xml 1105 1108 <span type="species:ncbi:10376">EBV</span>
Burkitt lymphoma (BL) is a B-cell tumor that arises as a consequence of chromosomal translocations that juxtapose the c-MYC proto-oncogene to Ig-gene enhancers, resulting in constitutive over-expression of c-MYC [1]. The endemic form of BL, furthermore, is highly associated (>90%) with latent infection by Epstein-Barr virus (EBV), though the precise contribution(s) of EBV to lymphomagenesis in this context is unclear. Cell lines derived from EBV-positive BL tumors, unlike EBV-immortalized B lymphoblastoid cell lines (LCLs), are not dependent on EBV for continued cell growth and proliferation, and maintain a restricted program of viral latent-infection gene expression known as Latency I, in which the only known viral protein expressed is the genome-maintenance protein, EBNA-1. In addition, the EBV small non-coding RNAs EBER-1 and EBER-2 are expressed, as are a family of alternatively spliced and potentially non-coding transcripts (BARTs) that are the precursors for a subgroup of the EBV miRNAs [2]-[4]. By contrast, LCLs (and some BL cell lines) support expression of the full complement of EBV latency-associated genes, i.e., the Latency III or Growth program.
###end p 5
###begin p 6
###xml 121 128 121 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 346 349 346 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-ThorleyLawson1">[5]</xref>
###xml 564 567 564 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Hochberg1">[6]</xref>
###xml 640 648 640 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 227 230 <span type="species:ncbi:10376">EBV</span>
###xml 283 286 <span type="species:ncbi:10376">EBV</span>
###xml 532 535 <span type="species:ncbi:10376">EBV</span>
###xml 658 661 <span type="species:ncbi:10376">EBV</span>
###xml 707 710 <span type="species:ncbi:10376">EBV</span>
Whereas Latency III represents viral gene expression that ensues for a limited time following infection of naive B cells in vivo, virus-driven establishment of latent infection within memory B cells (the long-term reservoir of EBV) is believed to result in the complete cessation of EBV protein expression, i.e., the Latency program (reviewed in [5]). However, upon periodic replication of latently infected memory cells (presumably to promote self renewal), reactivation of EBNA-1 expression occurs to prevent loss of the episomal EBV genome during cell division [6]. BL cell lines that maintain the Latency I program, therefore, offer an in vitro model of EBV latency that is representative of persistent EBV infection in its normal B cell host.
###end p 6
###begin p 7
###xml 327 330 323 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Nanbo1">[7]</xref>
###xml 439 442 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf1">[8]</xref>
###xml 477 480 473 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Nanbo1">[7]</xref>
###xml 625 628 621 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Samanta1">[9]</xref>
###xml 45 48 <span type="species:ncbi:10376">EBV</span>
###xml 194 197 <span type="species:ncbi:10376">EBV</span>
###xml 707 710 <span type="species:ncbi:10376">EBV</span>
###xml 852 855 <span type="species:ncbi:10376">EBV</span>
Herein, we employed this model of restricted EBV latency to address whether the virus may likely interfere with the type I interferon (IFN) response in normal B cells persistently infected with EBV. This work was initially prompted by a report that EBER expression in BL cells confers resistance to IFN-alpha-induced apoptosis [7], but that in our hands this was not mediated through inhibition of the dsRNA-activated protein kinase (PKR) [8], as had been previously concluded [7]. More recently, work from others suggests that the EBER RNAs themselves induce the expression of type I IFNs through direct activation of RIG-I [9]. We reasoned, therefore, that as a consequence of IFN induction by the EBERs, EBV may have evolved a mechanism to counter antiviral responses and other influences of IFN on cellular processes counterproductive to long-term EBV persistence.
###end p 7
###begin p 8
###xml 141 145 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Geiger1">[10]</xref>
###xml 1258 1262 1239 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhov1">[11]</xref>
###xml 1264 1268 1245 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova1">[12]</xref>
###xml 1486 1490 1460 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova1">[12]</xref>
###xml 1492 1496 1466 1470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 41 44 <span type="species:ncbi:10376">EBV</span>
###xml 532 535 <span type="species:ncbi:10376">EBV</span>
###xml 638 641 <span type="species:ncbi:10376">EBV</span>
###xml 685 688 <span type="species:ncbi:10376">EBV</span>
During Latency III, the LMP-1 protein of EBV inhibits the activation (Tyr phosphorylation) of the JAK kinase Tyk2 during IFN-alpha signaling [10]. We hypothesized, therefore, that a comparable inhibition of IFN-induced signaling may exist during Latency I (LMP-1 negative) to counter type I IFN production. However, contrary to our hypothesis, we report here that IFN-alpha-induced signaling, as measured by activating phosphorylation of STAT1 and STAT2 and the induction of IFN-stimulated gene (ISG) expression, is not affected by EBV in BL cells that maintain Latency I. We also did not observe evidence of IFN-alpha/beta production by EBV-infected B cells. Instead, we uncovered an EBV-independent and previously unknown defect in the negative feedback regulation of IFN-alpha signaling. This was evidenced by sustained Tyr phosphorylation of STAT1 and STAT2 and DNA-binding by ISGF3 (the STAT1- and STAT2-containing complex responsible for induction of ISG transcription), resulting in prolonged ISG expression following IFN treatment. Further, we demonstrate that the basis for this is an inability to adequately express the ubiquitin-specific protease UBP43 (itself encoded by an ISG) that deconjugates the ISG15 protein moiety from ISGylated proteins [11], [12], and which has previously been shown to inhibit type I IFN signaling by blocking STAT phosphorylation and consequently ISG induction through its direct displacement of the kinase JAK1 from the IFN-alpha/beta receptor [12], [13]. Thus, our data supports UBP43 as a primary negative regulator of IFN-alpha signaling. Finally, the naturally arising dysregulation of UBP43 expression described here, which to our knowledge has not been previously observed, occurs within a subset of BL cell lines derived from independent tumors, suggesting that it is not a random or isolated defect, but presumably one that confers an advantage to some BLs.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Dysregulation of ISG Expression in BL
###end title 10
###begin p 11
###xml 432 436 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Shimizu1">[14]</xref>
###xml 704 707 696 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Nanbo1">[7]</xref>
###xml 709 712 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf1">[8]</xref>
###xml 714 718 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Komano1">[15]</xref>
###xml 719 723 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf3">[18]</xref>
###xml 937 942 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 944 949 932 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG56</italic>
###xml 954 959 942 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG12</italic>
###xml 1252 1259 1240 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1A</xref>
###xml 1691 1695 1671 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf2">[17]</xref>
###xml 1718 1725 1698 1705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1A</xref>
###xml 2018 2023 1994 1999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 2066 2073 2042 2049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1B</xref>
###xml 65 68 <span type="species:ncbi:10376">EBV</span>
###xml 147 150 <span type="species:ncbi:10376">EBV</span>
###xml 283 286 <span type="species:ncbi:10376">EBV</span>
###xml 421 424 <span type="species:ncbi:10376">EBV</span>
###xml 450 453 <span type="species:ncbi:10376">EBV</span>
###xml 639 642 <span type="species:ncbi:10376">EBV</span>
###xml 1125 1128 <span type="species:ncbi:10376">EBV</span>
###xml 1168 1171 <span type="species:ncbi:10376">EBV</span>
###xml 1281 1284 <span type="species:ncbi:10376">EBV</span>
###xml 1434 1437 <span type="species:ncbi:10376">EBV</span>
###xml 1550 1553 <span type="species:ncbi:10376">EBV</span>
###xml 1652 1655 <span type="species:ncbi:10376">EBV</span>
###xml 1763 1766 <span type="species:ncbi:10376">EBV</span>
###xml 1856 1859 <span type="species:ncbi:10376">EBV</span>
###xml 1976 1979 <span type="species:ncbi:10376">EBV</span>
To investigate the potential impact of the restricted program of EBV latency-gene expression on the type I IFN response, we first examined whether EBV, and in particular the EBER RNAs, influences IFN-alpha induction of cellular gene expression. The cell model we chose was a pair of EBV-positive and -negative cell lines derived from Akata BL cells that, for reasons that are unclear, can spontaneously lose the episomal EBV genome [14]. Loss of the EBV genome from these cells, which maintain a Latency I program, results in decreased tumorigenic potential and reduced resistance to apoptosis in response to IFN-alpha, both properties of EBV-positive Akata cells that are largely dependent on the EBERs [7], [8], [15]-[18]. Following addition of IFN-alpha (100 U/ml) to Akata-cell cultures, cell samples were removed at 3 to 72 h for extraction of total RNA, which was then analyzed by northern blot hybridization for the expression of ISG15, ISG56 and ISG12. These ISGs were chosen based on an earlier microarray analysis that revealed constitutive (i.e., IFN-independent) expression of their mRNAs to be down-regulated in EBV-positive Akata cells relative to their EBV-negative counterparts (I.K.R. and J.T.S., unpublished observation). As shown in Fig. 1A (left panel), in the EBV-negative cells, IFN-alpha-induced ISG expression was not only substantially higher, it was also sustained for an additional 24-48 h, suggesting that EBV infection may suppress IFN-alpha signaling. To address this possibility, we repeated the analysis with the same EBV-negative cells (A.2) engineered to stably express the EBERs at physiologic levels, along with the EBV genome-maintenance protein, EBNA-1 [17]. However, as shown in Fig. 1A (right panel), the presence of these EBV gene products did not affect the intensity or duration of ISG expression in an otherwise EBV-negative background, suggesting that the different responses of these BL lines to IFN-alpha are not attributable to EBV (see also below). A quantification of ISG15 expression in these cells is presented in Fig. 1B.
###end p 11
###begin title 12
###xml 56 59 <span type="species:ncbi:10376">EBV</span>
###xml 73 76 <span type="species:ncbi:10376">EBV</span>
Differential induction of ISG mRNA in IFN-alpha-treated EBV-negative and EBV-positive Akata BL cell lines.
###end title 12
###begin p 13
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG56</italic>
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG12</italic>
###xml 546 547 538 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 552 553 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 689 694 681 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 55 58 <span type="species:ncbi:10376">EBV</span>
###xml 78 81 <span type="species:ncbi:10376">EBV</span>
###xml 125 128 <span type="species:ncbi:10376">EBV</span>
###xml 475 478 <span type="species:ncbi:10376">EBV</span>
###xml 543 546 <span type="species:ncbi:10376">EBV</span>
A) Northern blot analysis of ISG15, ISG56 and ISG12 in EBV-negative (A.2) and EBV-positive (A.15) BL cells (left panel), and EBV-negative A.2 vector-control and EBER-expressing BL cells (right panel) following treatment with IFN-alpha (100 units/ml) for up to 72 h. Each lane contained 10 microg total cellular RNA. Analysis of the expression level of each RNA was determined by sequential probing of a single blot for each cell line. EBER expression was analyzed to confirm EBV status in A.15 cells and to determine EBER expression levels in EBV-/EBER+ cells. Levels of 28S rRNA were analyzed to ensure equivalent RNA loading and integrity. B) Quantification by phosphorimage analysis of ISG15 mRNA levels from (A). Results are representative of two independent experiments.
###end p 13
###begin p 14
###xml 374 378 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kelly1">[19]</xref>
###xml 411 416 407 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 434 440 430 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">Fig. 2</xref>
###xml 514 520 510 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1</xref>
###xml 576 581 572 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 733 740 725 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Figs. 1</xref>
###xml 745 746 737 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">2</xref>
###xml 1128 1133 1120 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EBERs</italic>
###xml 1135 1140 1127 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BARTs</italic>
###xml 43 46 <span type="species:ncbi:10376">EBV</span>
###xml 106 109 <span type="species:ncbi:10376">EBV</span>
###xml 254 257 <span type="species:ncbi:10376">EBV</span>
###xml 482 485 <span type="species:ncbi:10376">EBV</span>
###xml 614 617 <span type="species:ncbi:10376">EBV</span>
###xml 789 792 <span type="species:ncbi:10376">EBV</span>
###xml 872 875 <span type="species:ncbi:10376">EBV</span>
###xml 1168 1171 <span type="species:ncbi:10376">EBV</span>
To further assess a potential influence of EBV, we measured the response to IFN-alpha by three additional EBV-positive BL cell lines that maintain a Latency I program (KemI, SavI and MutuI), as well as one line (OkuI) that maintains a similar pattern of EBV latency-gene expression (Wp-restricted latency), but which also expresses the three EBNA-3 proteins (3A, 3B and 3C) [19]. As revealed by the analysis of ISG15 mRNA expression (Fig. 2), KemI and OkuI cells were equivalent to EBV-positive Akata cells (as in Fig. 1), whereas SavI cells exhibited sustained expression of ISG15 comparable to that observed for EBV-negative Akata cells; MutuI cells appeared to support an intermediate response to IFN-alpha. The data presented in Figs. 1 and 2, therefore, argue against an influence of EBV on the type I IFN induction of gene expression during the Latency I program of EBV infection, though we cannot rule-out the possibility that differences observed here were in fact due to the expression of a viral gene(s) that is not uniformly expressed in BL cells that otherwise maintain a Latency I program (i.e., other than EBNA-1, EBERs, BARTs and a subpopulation of the EBV miRNAs).
###end p 14
###begin title 15
###xml 36 41 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 74 77 <span type="species:ncbi:10376">EBV</span>
Differential IFN-alpha induction of ISG15 mRNA expression among non-Akata EBV-positive BL cell lines.
###end title 15
###begin p 16
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
ISG15 mRNA levels were analyzed from total RNA extracted from KemI, SavI, OkuI and MutuI BL cells that had been treated or not with IFN-alpha for 3-72 h. Data shown is representative of at least two independent experiments for each cell line.
###end p 16
###begin title 17
Aberrant ISG Expression is Transcriptional
###end title 17
###begin p 18
###xml 268 274 264 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1</xref>
###xml 471 476 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 730 737 714 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g003">Fig. 3A</xref>
###xml 869 874 853 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1287 1294 1263 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g003">Fig. 3B</xref>
###xml 1785 1789 1757 1761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Yasukawa1">[20]</xref>
###xml 158 161 <span type="species:ncbi:10376">EBV</span>
###xml 591 594 <span type="species:ncbi:10376">EBV</span>
###xml 710 713 <span type="species:ncbi:10376">EBV</span>
###xml 972 975 <span type="species:ncbi:10376">EBV</span>
###xml 995 998 <span type="species:ncbi:10376">EBV</span>
###xml 1101 1104 <span type="species:ncbi:10376">EBV</span>
###xml 1267 1270 <span type="species:ncbi:10376">EBV</span>
We next considered the mechanistic basis for the observed differences in ISG expression. A comparative array analysis of IFN-alpha-induced gene expression in EBV-negative and -positive Akata cells had indicated that the majority of ISGs behaved like those analyzed in Fig. 1 (data not shown), suggesting that the differences we observed were due primarily to a common alteration in IFN-alpha-induced transcription. In support of this, we observed effects of IFN-alpha on ISG15 promoter-driven reporter expression that paralleled the effects of IFN-alpha on endogenous ISG mRNA expression in EBV-negative and -positive Akata cells, i.e., induction of reporter expression was greater and sustained longer in the EBV-negative cells (Fig. 3A). Further, analysis by EMSA of the binding of ISGF3 (a complex of STAT1, STAT2 and IRF9) to a DNA probe containing the ISRE of the ISG15 promoter indicated that IFN-alpha-induced binding to the probe was equivalent within extracts of EBV-negative (A.2) and EBV-positive (A.15) Akata cells for at least 4 h following addition of IFN-alpha. However, in contrast to EBV-negative cells in which binding was sustained for 24 h post-induction, ISGF3 binding was slightly reduced at 8 h and barely detectable at 24 h within extracts of EBV-positive cells (Fig. 3B). Collectively, these data indicated that differences in ISG expression in these BL cells are not due to a defect in the induction of gene expression by IFN-alpha, but rather an inability to sustain generation of ISGF3 (as in A.15 cells) or a block in the turnover of this transcriptionally active protein complex (as possible in A.2 cells). Given that the latter is considered part of the normal negative feedback restriction of the inductive phase of the type I IFN response (reviewed in [20]), we favored the conclusion that sustained expression of ISG transcription in a subset of BL lines, i.e., beyond several hours post induction, is an aberrant response.
###end p 18
###begin title 19
###xml 9 14 9 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 81 84 81 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG</italic>
Elevated ISG15 promoter and ISGF3 DNA-binding activities correspond to sustained ISG expression.
###end title 19
###begin p 20
###xml 83 88 79 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 98 101 94 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hGH</italic>
###xml 593 595 573 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 717 722 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 477 480 <span type="species:ncbi:10376">EBV</span>
###xml 498 501 <span type="species:ncbi:10376">EBV</span>
A) A.2 and A.15 Akata BL cells were transfected in triplicate with 10 microg of an ISG15 promoter-hGH reporter plasmid; after 14 h, IFN-alpha (100 units/ml) was added to half of the transfected cells and expression of hGH was determined in duplicate by radioimmunoassay at 4, 8, 24 and 48 h post-IFN-alpha addition. Results shown are representative of three independent experiments. B) EMSAs were performed with increasing amounts of protein (4, 8 or 16 microg) extracted from EBV-negative A.2 and EBV-positive A.15 Akata BL cells that had been treated with IFN-alpha for 0, 4, 8 or 24 h; the 32P-labeled double-stranded oligodeoxynucleotide probe contained the interferon-stimulated response element (ISRE) from the ISG15 promoter.
###end p 20
###begin title 21
STAT Phosphorylation is Prolonged in Cells that Sustain ISG Expression
###end title 21
###begin p 22
###xml 330 337 326 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Figs. 1</xref>
###xml 342 343 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g003">3</xref>
###xml 530 536 526 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Fig. 4</xref>
###xml 755 759 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Wen1">[21]</xref>
###xml 812 818 808 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Fig. 4</xref>
###xml 1019 1023 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Der1">[22]</xref>
###xml 1116 1122 1104 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Fig. 4</xref>
###xml 1386 1393 1370 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g003">Fig. 3B</xref>
Having determined that aberrant ISG expression is most likely due to sustained transcriptional activation by ISGF3, we next assessed the status of the components of this complex - STAT1, STAT2 and IRF9 - within IFN-alpha-treated cells that exhibited either normal or abnormal ISG expression. Consistent with the data presented in Figs. 1 and 3, within A.2 Akata cells (prolonged ISG expression) we observed sustained tyrosine phosphorylation of STAT1 (Tyr701) and STAT2 (Tyr689) throughout the 48-h time course of the experiment (Fig. 4). By contrast, within A.15 cells tyrosine phosphorylation of both proteins was dramatically reduced after 4 h, as expected. Phosphorylation of Ser727 on STAT1, which is not essential for STAT1 transcriptional activity [21], did not differ notably between A.2 and A.15 cells (Fig. 4). Expression of IRF9, the DNA-binding component of ISGF3 that does not require phosphorylation for activity, was equivalent in both cell lines prior to addition of IFN-alpha. Encoded by an ISG itself [22], IRF9 levels were lower in A.15 cells at later times post IFN-alpha treatment, as expected (Fig. 4). Thus, tyrosine phosphorylation or its absence on STATs 1 and 2 within A.2 and A.15 Akata cells at later times post IFN-alpha treatment was in good agreement with the detection or lack of ISGF3 binding to a classic ISRE in extracts of these cells, respectively (Fig. 3B), suggesting that sustained phosphorylation is the basis for prolonged ISG expression in A.2 cells.
###end p 22
###begin title 23
Tyrosine phosphorylation of STAT1 and STAT2 is prolonged in IFN-alpha-stimulated A.2 cells.
###end title 23
###begin p 24
###xml 33 36 33 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">701</sup>
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">727</sup>
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">689</sup>
###xml 123 126 <span type="species:ncbi:10376">EBV</span>
###xml 144 147 <span type="species:ncbi:10376">EBV</span>
A) Phosphorylation of STAT1 (pTyr701 and pSer727) and STAT2 (pTyr689) in response to IFN-alpha (100 U/ml) was monitored in EBV-negative A.2 and EBV-positive A.15 Akata BL cells by immunoblotting with phospho-specific antibodies. Blots were subsequently stripped and reprobed to detect total STAT1 and STAT2, as well as IRF9 and beta-actin (loading control). B) Quantification of the ratio of phosphorylated STAT to total STAT (phospho:total) at 4 and 24 hours post-IFN addition on blots from (A).
###end p 24
###begin p 25
###xml 491 498 487 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g005">Figs. 5</xref>
###xml 503 505 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006023.s001">S1</xref>
###xml 684 690 680 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">Fig. 2</xref>
###xml 1016 1021 1012 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1034 1040 1030 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">Fig. 2</xref>
###xml 1113 1120 1109 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006023.s001">Fig. S1</xref>
###xml 401 404 <span type="species:ncbi:10376">EBV</span>
###xml 433 436 <span type="species:ncbi:10376">EBV</span>
###xml 739 742 <span type="species:ncbi:10376">EBV</span>
###xml 775 778 <span type="species:ncbi:10376">EBV</span>
###xml 926 929 <span type="species:ncbi:10376">EBV</span>
To determine if this abnormal regulation of STAT phosphorylation is common to other BL cells that exhibited sustained ISG expression, we extended analysis of IFN-alpha-induced STAT1 Tyr701 phosphorylation to MutuI and SavI, which exhibited intermediate and sustained ISG responses, respectively, relative to A.2 Akata cells. We also assessed two additional and independently derived pair of subclonal EBV-negative (Ak- and 2A8-) and EBV-positive (Ak+ and 2A8+) Akata cell lines. As shown in Figs. 5 and S1, phosphorylation of STAT1 in MutuI and SavI BL cells was indeed sustained for at least 24 h, consistent with the prolonged ISG expression observed previously in these cells (see Fig. 2). Interestingly, unlike A.2 cells, Ak- and 2A8- EBV-negative Akata cells (and their EBV-positive counterparts) did not exhibit prolonged STAT1 phosphorylation, providing further evidence that the type I IFN response is not targeted by EBV during the Latency I program. Further, KemI cells, which exhibited a normal course of ISG15 expression (Fig. 2), also exhibited normal kinetics of STAT1 phosphorylation, as expected (Fig. S1).
###end p 25
###begin title 26
###xml 72 77 72 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
Duration of tyrosine phosphorylation of STAT1 correlates with sustained ISG15 expression following IFN treatment.
###end title 26
###begin p 27
###xml 138 144 134 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Fig. 4</xref>
###xml 460 467 456 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Figs. 4</xref>
###xml 472 473 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g007">7</xref>
###xml 567 570 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">701</sup>
###xml 705 712 701 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006023.s001">Fig. S1</xref>
###xml 218 221 <span type="species:ncbi:10376">EBV</span>
###xml 241 244 <span type="species:ncbi:10376">EBV</span>
SavI and MutuI cells were treated with IFN-alpha for up to 24 h. Tyrosine phosphorylation of STAT1 was monitored by immunoblotting, as in Fig. 4, and then stripped and probed for total STAT1. A separate matched set of EBV-positive (Ak+) and EBV-negative (Ak-) Akata BL cells was also evaluated for STAT1 tyrosine phosphorylation and total STAT1 levels. Note: the Ak-/Ak+ blot was probed with a different lot of anti-phosho STAT1 antibody than used above or in Figs. 4 and 7. This antibody detected a nonspecific band (designated NS) with very similar mobility to pTyr701 STAT1. This band is unlikely to be a degradation product of STAT1 as we did not see this band using earlier lots of the antibody (see Fig. S1). The blots for beta-actin served as protein loading controls.
###end p 27
###begin title 28
Sustained STAT1 Phosphorylation is Due to Inadequate UBP43 Expression
###end title 28
###begin p 29
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Krebs1">[23]</xref>
Physiologic down-regulation of IFN-induced gene expression can occur through several mechanisms. Among these, two that we are aware of have a direct negative influence on the phosphorylation of STAT proteins by type I IFNs, as observed here. The first is the well established abrogation of STAT1 phosphorylation by suppressor of cytokine signaling 1 (SOCS1), itself an ISG protein [23]. We initially asked, therefore, whether a deficiency in SOCS1 expression might be responsible for sustained phosphorylation of STAT proteins in cells that support prolonged ISG expression. However, we observed no difference in constitutive SOCS1 expression, and IFN-alpha-induced expression of SOCS1 was actually slightly lower in A.15 relative to A.2 cells (data not shown), arguing against involvement of SOCS1 (assuming SOCS1 is biochemically active in A.2 and similar BL cell lines).
###end p 29
###begin p 30
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 388 394 384 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Fig. 1</xref>
###xml 399 404 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 406 411 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG56</italic>
###xml 416 421 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG12</italic>
###xml 475 480 467 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 600 605 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 688 693 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 973 979 957 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g006">Fig. 6</xref>
###xml 1248 1251 <span type="species:ncbi:10376">EBV</span>
###xml 1286 1289 <span type="species:ncbi:10376">EBV</span>
###xml 1425 1428 <span type="species:ncbi:10376">EBV</span>
The second mechanism is the recently described inhibition of STAT1 phosphorylation by UBP43 (the product of ISG43) through its inhibition of JAK1 interaction with the IFNAR2 subunit of the type I IFN receptor [13]. Serendipitously, ISG43 was one of the ISGs we initially selected to monitor in our assessment of IFN-alpha-induced transcription. Interestingly, unlike the results shown in Fig. 1 for ISG15, ISG56 and ISG12, we observed little or no IFN-alpha induction of the ISG43 mRNA by northern blotting in A.2 Akata cells (which exhibited high and prolonged ISG expression), whereas induction of ISG43 expression was easily detectable in A.15 cells (data not shown). Thus, lack of an ISG43-encoded function might be responsible for the inability to efficiently terminate IFN-alpha-induced transcription in a subset of BL cells. To address the potential role of UBP43, we first assessed induction of its mRNA by IFN-alpha in our full panel of BL cell lines. As shown in Fig. 6, the induction of UBP43 mRNA expression was very low in all cell lines analyzed that exhibit prolonged ISG expression (A.2, SavI and MutuI), while notably higher in the lines that support normal kinetics of ISG expression. The latter group also included an additional EBV-negative Akata line (2A8) and its EBV-reinfected counterpart (2A8.1), providing further evidence that differences in IFN-alpha-induced gene expression (including UBP43) are EBV-independent.
###end p 30
###begin title 31
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
Reduction of UBP43 mRNA corresponds to sustained ISG expression in BL cells.
###end title 31
###begin p 32
###xml 125 130 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
###xml 159 162 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S14</italic>
###xml 191 196 187 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
###xml 201 204 197 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S14</italic>
Total RNA was isolated from the indicated cell lines pre- and post-IFN-alpha treatment for 24 h and subjected to RT-PCR with UBP43- and ribosomal protein gene S14-specific primers. Amplified UBP43 and S14 (control for RNA integrity and amplification efficiency) cDNAs were detected by Southern blotting and ethidium bromide staining, respectively. Equivalent results were obtained in multiple independent experiments.
###end p 32
###begin p 33
###xml 485 491 477 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g007">Fig. 7</xref>
###xml 730 733 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 725 733 717 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ubp43<sup>&#8722;/&#8722;</sup></italic>
###xml 740 744 732 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova1">[12]</xref>
###xml 746 750 738 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Randall1">[24]</xref>
Having demonstrated a direct correlation between the level of UBP43 mRNA induction and extent of ISG expression, we next tested whether exogenous expression of UBP43 could suppress IFN-alpha-induced phosphorylation of STAT1 in BL cells (A.2) in which phosphorylation is otherwise sustained. To do this, we stably expressed FLAG-tagged UBP43 in A.2 Akata cells, and compared IFN-alpha-induced phosphorylation of STAT1 on Tyr701 in these cells to a vector-only control line. As shown in Fig. 7, UBP43 expression caused a dramatic reduction in the amount of phosphorylated relative to total STAT1, consistent with the previous reports of UBP43-mediated inhibition of STAT1 phosphorylation and sustained STAT1 phosphorylation in Ubp43-/- cells [12], [24]. We conclude, therefore, that the inability to efficiently terminate IFN-alpha-induced signaling in a subset of BLs is due to insufficient expression of UBP43.
###end p 33
###begin title 34
Constitutive expression of UBP43 reduces the induction and duration of IFN-alpha-induced tyrosine phosphorylation of STAT1.
###end title 34
###begin p 35
A.2 pCR3.1 (vector control) and A.2 UBP43 cells were treated with IFN-alpha (100 U/ml) for up to 24 h. Phosphorylated (pTyr) and total STAT1, FLAG-tagged UBP43 and beta-actin (loading control) were detected by immunoblotting. Data shown is representative of three independent experiments.
###end p 35
###begin title 36
Discussion
###end title 36
###begin p 37
###xml 959 964 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 1138 1143 1130 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 1253 1256 1245 1248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1248 1256 1240 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ubp43<sup>&#8722;/&#8722;</sup></italic>
###xml 1291 1295 1283 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova1">[12]</xref>
###xml 161 164 <span type="species:ncbi:10376">EBV</span>
###xml 282 285 <span type="species:ncbi:10376">EBV</span>
###xml 386 389 <span type="species:ncbi:10376">EBV</span>
###xml 431 434 <span type="species:ncbi:10376">EBV</span>
###xml 1257 1263 <span type="species:ncbi:10090">murine</span>
###xml 1716 1719 <span type="species:ncbi:10376">EBV</span>
Here we report that a subpopulation of B-cell lines derived from BL tumors exhibit abnormally long IFN-alpha induction of gene expression that is independent of EBV infection. Although we cannot formally rule out the possibility that the observed differences in ISG induction among EBV-positive BL cells might be attributable to expression of viral genes not uniformly expressed in all EBV-positive BL cells, our finding that some EBV-negative BL cells also exhibit these differences in ISG induction supports the idea that this is indeed a virus-independent effect. This atypical response to IFN-alpha induction is associated with prolonged tyrosine phosphorylation on STAT1 and STAT2 and, consistent with the presence of these activated STAT proteins, extended DNA-binding activity of the ISGF3 complex, as well as higher and sustained expression of an ISRE-driven reporter gene. An exception to the generally sustained ISG expression in these BL cells was ISG43, which was minimally induced in all lines supporting prolonged ISG expression. This, and reports that the ubiquitin-specific protease UBP43 (alternatively USP18) encoded by ISG43 can block type I IFN-induced phosphorylation of Tyr701 on STAT1 and that ISG expression is prolonged in ubp43-/- murine embryonic fibroblast cells [12], led us to examine whether inadequate induction of UBP43 expression is the basis for our observations. Indeed, stable expression of UBP43 in our variant BL cells substantially reduced IFN-alpha activation of STAT1. Thus, we conclude that a defect in the IFN-inducible expression of UBP43 results in a significant delay of the negative feedback control of type I IFN signaling in these tumor cells, irrespective of their EBV status.
###end p 37
###begin p 38
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhov1">[11]</xref>
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Loeb1">[25]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kim1">[26]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Osiak1">[28]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 1048 1053 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
###xml 1080 1084 1072 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kang1">[29]</xref>
###xml 1086 1090 1078 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Li1">[30]</xref>
###xml 1199 1204 1191 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1335 1340 1327 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG43</italic>
UBP43 removes the ubiquitin-like protein encoded by ISG15 that is conjugated to proteins in a process known as ISGylation [11], [25]. The biological importance of IFN-induced ISGylation is not fully understood, as it is not required for type I IFN signal transduction, ISG expression, or IFN-mediated antiviral functions [13], [26]-[28]. The isopeptidase activity of UBP43 responsible for deconjugation of ISG15ylated proteins, however, is not required for the inhibition of STAT1 phosphorylation, which appears to be mediated instead through direct inhibition by UBP43 of the interaction of JAK1 with the type I IFN receptor [13]. The defect in the UBP43-mediated negative feedback control of IFN signaling that we have uncovered is in the IFN-alpha-induced expression of UBP43, either in the transcriptional activation of the UBP43 gene by IFN-alpha, or in a co- or post-transcriptional event that results in a specific reduction in UBP43 mRNA production. On the surface, a defect in IFN-induced transcription would appear less likely given that ISG43 is an immediate-early ISG [29], [30] and that there is not an apparent defect in classic ISGF3 activation of ISG transcription (e.g., as that of ISG15). However, we cannot rule out loss of contribution by an additional factor(s) needed for appropriate IFN-induced transcription of ISG43, but which is not required for the expression of the ISG family in general. Currently, however, little is known about the specific regulation of UBP43 expression at the transcriptional level.
###end p 38
###begin p 39
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhov1">[11]</xref>
###xml 290 294 290 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Randall1">[24]</xref>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Osiak1">[28]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kim2">[31]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ritchie1">[32]</xref>
###xml 773 777 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Der1">[22]</xref>
###xml 887 891 887 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kang1">[29]</xref>
###xml 893 897 893 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Liu1">[33]</xref>
###xml 899 903 899 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Schwer1">[34]</xref>
###xml 917 920 917 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 912 920 912 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ubp43<sup>&#8722;/&#8722;</sup></italic>
###xml 1087 1091 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova1">[12]</xref>
###xml 1093 1097 1093 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Knobeloch1">[27]</xref>
###xml 1099 1103 1099 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Rempel1">[35]</xref>
###xml 1105 1109 1105 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ritchie2">[36]</xref>
###xml 1228 1233 1228 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1300 1304 1300 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 1306 1310 1306 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kim1">[26]</xref>
###xml 1312 1316 1312 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Knobeloch1">[27]</xref>
###xml 1859 1861 1859 1861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1)</italic>
###xml 1958 1962 1958 1962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Liu1">[33]</xref>
###xml 1964 1966 1964 1966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2)</italic>
###xml 2037 2041 2037 2041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Liu1">[33]</xref>
###xml 2043 2047 2043 2047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Schwer1">[34]</xref>
###xml 2053 2055 2053 2055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3)</italic>
###xml 2158 2161 2158 2161 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2153 2161 2153 2161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ubp43<sup>&#8722;/&#8722;</sup></italic>
###xml 2167 2171 2167 2171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Yan1">[37]</xref>
###xml 921 925 <span type="species:ncbi:10090">mice</span>
###xml 2162 2166 <span type="species:ncbi:10090">mice</span>
An obvious question raised by our findings is what advantage is conferred to a cell, normal or transformed, from a sustained response to type I IFNs? While UBP43 deficiency results in extended expression of ISGs, leading to increased resistance to viral and some bacterial infections [11], [24], [28], [31], [32], it is difficult to rationalize heightened resistance to potential infection as the primary pressure to dysregulate UBP43 expression. Alternatively, suboptimal expression of UBP43, and the resulting delay in the negative feedback regulation of IFN signaling, may promote a beneficial IFN-dependent function not necessarily related to the antiviral response. Of the several hundred known ISGs, clearly not all are involved in mediating resistance to infections [22]. Further, UBP43 is constitutively expressed in liver, cells of the monocytic lineage and within fetal spleen [29], [33], [34], and in Ubp43-/- mice the complete lack of UBP43 expression is associated with elevated ISG15-conjugation and cellular necrosis in brain that results in severe neurological disorders [12], [27], [35], [36]. Thus, UBP43 appears to also contribute to a homeostatic (i.e., IFN-independent) regulation of ISGylation, though the ISG15 gene does not appear to be required for these detrimental effects [13], [26], [27]. Thus, given the generally detrimental effect that prolonged IFN signaling would have on a cell, and the negative consequences UBP43 deficiency has in some tissues, it would seem that dysregulation of UBP43 as reported here would have greater relevance in the setting of oncogenesis and tumor maintenance, as transformed cells are characteristically resistant to at least some of the negative properties of IFN, such as antiproliferative and proapoptotic effects. Though few, there have been reports of UBP43 function related to oncogenesis: 1) A UBP43-mediated block in cytokine-induced terminal differentiation of the myeloid cell line M1 [33]; 2) A potential anti-neoplastic influence in acute promyelocytic leukemia [33], [34]; and 3) Resistance to BCR-ABL induction of a chronic myeloid leukemia-like myeloproliferative disease in Ubp43-/- mice [37]. Of these, only the second report is consistent with a potentially pro-oncogenic consequence of UBP43 deficiency. However, this specific example would appear to have little relevance to BL.
###end p 39
###begin p 40
###xml 266 269 262 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Nanbo1">[7]</xref>
###xml 271 274 267 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf1">[8]</xref>
###xml 401 404 390 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Samanta1">[9]</xref>
###xml 810 814 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Geiger1">[10]</xref>
###xml 1243 1250 1221 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Figs. 4</xref>
###xml 1255 1256 1233 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g005">5</xref>
###xml 1319 1326 1297 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g001">Figs. 1</xref>
###xml 1328 1329 1306 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">2</xref>
###xml 1334 1335 1312 1313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g006">6</xref>
###xml 1363 1368 1341 1346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1439 1445 1413 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g002">Fig. 2</xref>
###xml 1486 1491 1460 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 1519 1523 1493 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Der1">[22]</xref>
###xml 97 100 <span type="species:ncbi:10376">EBV</span>
###xml 226 229 <span type="species:ncbi:10376">EBV</span>
###xml 537 540 <span type="species:ncbi:10376">EBV</span>
###xml 765 768 <span type="species:ncbi:10376">EBV</span>
###xml 888 891 <span type="species:ncbi:10376">EBV</span>
###xml 1029 1032 <span type="species:ncbi:10376">EBV</span>
###xml 1747 1750 <span type="species:ncbi:10376">EBV</span>
Our original intent for these studies was to determine whether the restricted latency program of EBV interferes with the type I IFN response, the impetus for which were findings from our group and others that the EBER RNAs of EBV inhibit IFN-alpha-induced apoptosis [7], [8], and reports from Takada and colleagues that the EBERs induce expression of IFN-alpha/beta through direct activation of RIG-I [9]. Specifically, the latter suggested to us that, given the potent antiviral properties of the type I IFNs, it is quite possible that EBV negatively targets the IFN-alpha-mediated signaling that would be initiated as a consequence of EBER induction of type I IFN expression. However, in contrast to the inhibition of type I IFN signaling by the LMP-1 protein of EBV during the growth or Latency III program [10], we found no evidence of such an effect in this cell model of restricted EBV latency. Interestingly, we also saw no indication of significant IFN-alpha/beta production either from latently infected BL cells, or by EBV-negative BL cells that stably express the EBER RNAs (in addition to EBNA-1) at physiologic levels. Specifically, we did not detect tyrosine phosphorylation of either STAT1 or STAT2 in the absence of added IFN (Figs. 4 and 5), and consistent with this, little or no ISG mRNA expression (Figs. 1, 2 and 6). Note that a low level of ISG15 mRNA detected in the absence of IFN-alpha (as in KemI and SavI cells, Fig. 2) is consistent with basal expression of ISG15 and a subset of other ISGs [22]. Further, and consistent with the lack of detectable STAT1/2 phosphorylation in these BL cells, we have been consistently unable to directly detect IFN-alpha production (by ELISA) from our panel of BL cell lines, including EBV-negative Akata cells that stably express both EBERs (data not shown).
###end p 40
###begin p 41
###xml 365 368 365 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Samanta1">[9]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Fok1">[38]</xref>
###xml 943 946 940 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Samanta1">[9]</xref>
###xml 521 524 <span type="species:ncbi:10376">EBV</span>
###xml 692 695 <span type="species:ncbi:10376">EBV</span>
###xml 769 772 <span type="species:ncbi:10376">EBV</span>
###xml 819 822 <span type="species:ncbi:10376">EBV</span>
This apparent discrepancy with the earlier report may be due to the different experimental systems employed. Notably, the previous studies implicating EBER-induction of type I IFN production through direct activation of RIG-I relied on transfection (by electroporation) for the expression of EBERs and/or a GFP-tagged version of RIG-I (RIG-I/GFP) to show an effect [9]. This may have resulted in a functional interaction between the otherwise nuclear EBERs [38] and cytoplasmic RIG-I that normally would not occur during EBV latency. The activation of endogenous RIG-I (as evidenced by type I IFN expression) was not assessed in BL cells stably expressing the EBERs either naturally from the EBV genome, or by stable expression from an exogenously introduced vector in EBV-negative BL cells. Further, upon infection of EBV-negative BL cells, induction of IFN-beta RNA expression could only be detected in cells stably overexpressing RIG-I/GFP [9]. Thus, it would appear that induction of type I IFNs by the EBERs is not a normal function of these noncoding RNAs, at least within the context of BL cells.
###end p 41
###begin p 42
###xml 1154 1158 1154 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Malakhova2">[13]</xref>
###xml 1160 1164 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kim1">[26]</xref>
###xml 1166 1170 1166 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Knobeloch1">[27]</xref>
###xml 1172 1176 1172 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Rempel1">[35]</xref>
###xml 264 267 <span type="species:ncbi:10376">EBV</span>
###xml 333 336 <span type="species:ncbi:10376">EBV</span>
###xml 448 451 <span type="species:ncbi:10376">EBV</span>
In conclusion, we have uncovered a defect in the negative feedback control of type I IFN signaling by the ISG15-specific isopeptidase UBP43 within BL cells. This is unlikely to represent a common cellular adaptation to enhance an IFN-induced antiviral response to EBV or other infectious agents, as it does not occur uniformly among EBV-positive BL cell lines, and such an antiviral response would likely be inconsistent with the high incidence of EBV infection associated with endemic BL. Further, the observation that the underlying mechanism of prolonged IFN signaling is also evident in several cell lines derived from independent tumors suggests that this is not a random isolated event, but rather that dysregulation of UBP43 expression confers relatively frequently an advantage to some tumor cells, though what this advantage may be is currently unclear. However, because UBP43 is not constitutively expressed in BL cells, we presume that any such advantage may lie in the effect that IFN-induced ISG15ylation has on protein function. While earlier studies have relied on gene knock-out technology to elucidate the biochemical functions of UBP43 [13], [26], [27], [35], this is the first instance that we are aware of in which a natural deficiency in UBP43 expression was observed. BL lines that exhibit a defect in the type I IFN-induced expression of UBP43 may therefore provide a useful model to further probe the biological roles of UBP43 and ISGylation and their contributions to cell biology.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
Cell Culture and Plasmids
###end title 44
###begin p 45
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf2">[17]</xref>
###xml 661 665 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf2">[17]</xref>
###xml 667 671 667 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Ruf3">[18]</xref>
###xml 681 682 681 682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 704 705 704 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 941 945 941 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Kelly1">[19]</xref>
###xml 1267 1337 1267 1337 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACGTGGATCCGCCACCATGGATTACAAGGATGACGACGATAAGAGCAAGGCGTTTGGGCTCCTG-3&#8242;</named-content>
###xml 1342 1379 1342 1379 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCCTCGAGTAGAAGACTCCGTAGATCCAG-3&#8242;</named-content>
###xml 1438 1441 1438 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bam</italic>
###xml 1448 1451 1448 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 1470 1473 1470 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bam</italic>
###xml 1481 1484 1481 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 1669 1670 1669 1670 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1724 1728 1724 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Sample1">[39]</xref>
###xml 104 110 <span type="species:ncbi:9913">bovine</span>
###xml 162 165 <span type="species:ncbi:10376">EBV</span>
###xml 468 471 <span type="species:ncbi:10376">EBV</span>
###xml 608 611 <span type="species:ncbi:10376">EBV</span>
###xml 684 687 <span type="species:ncbi:10376">EBV</span>
###xml 707 710 <span type="species:ncbi:10376">EBV</span>
###xml 792 795 <span type="species:ncbi:10376">EBV</span>
###xml 856 859 <span type="species:ncbi:10376">EBV</span>
Cells were maintained in RPMI 1640 medium containing 2 mM L-glutamine (Mediatech) and 10% defined fetal bovine serum (HyClone). Akata A.2 and A.15 cell lines are EBV-negative and -positive derivatives, respectively, of the parental Akata BL cell line. A.2.EBER and A.2.Vector are A.2 Akata cells that stably express physiologic levels of EBER-1 and EBER-2, or which contain an empty EBER expression vector, respectively [17]. Cell line 2A8 is an independently-derived EBV-negative Akata clone (gift of J.W. Sixbey). Isolation and characterization of all Akata cell lines, as well as re-infection of 2A8 with EBV to generate 2A8.1, has been previously described [17], [18]. Akata Ak- (EBV-negative) and Ak+ (EBV-positive) cell lines were kindly provided by K. Takada. KemI, SavI and MutuI are EBV-positive BL cell lines that maintain a Latency I program of EBV gene expression; OkuI BL cells are similar, but also express EBNAs 3A, 3B and 3C [19]. To establish an A.2 cell line that constitutively expressed UBP43, the UBP43 open reading frame was generated by PCR from a sequence-verified full-length cDNA purchased from Open Biosystems. PCR primers were designed to incorporate an N-terminal FLAG epitope as well as restriction sites for cloning. Primers used were: 5'-ACGTGGATCCGCCACCATGGATTACAAGGATGACGACGATAAGAGCAAGGCGTTTGGGCTCCTG-3' and 5'-GATCCTCGAGTAGAAGACTCCGTAGATCCAG-3'. Following amplification, PCR products were digested with BamHI and XhoI, and cloned into BamHI- and XhoI-digested pCR3.1 (Invitrogen) to generate an expression vector encoding FLAG-UBP43. Ten micrograms of FLAG-UBP43 or pCR3.1 (to generate vector-control lines) was used to transfect 8x106 A.2 cells by electroporation as described previously [39]. Stable transfectants were selected in 200 microg of G418 per ml. Following selection and expansion of cells, clones expressing UBP43 were identified by immunoblotting with anti-FLAG antibody (M2; Sigma).
###end p 45
###begin title 46
Analysis of RNA Expression
###end title 46
###begin p 47
###xml 174 175 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 624 626 616 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1232 1237 1216 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
###xml 1265 1268 1249 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S14</italic>
###xml 1294 1321 1278 1305 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGCAAGGCGTTTGGGCTCCTG-3&#8242;</named-content>
###xml 1326 1363 1310 1347 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCCTCGAGTAGAAGACTCCGTAGATCCAG-3&#8242;</named-content>
###xml 1370 1398 1354 1382 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCAGACCGAGATGAATCCTCA-3&#8242;</named-content>
###xml 1403 1430 1387 1414 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGGTCCAGGGGTCTTGGTCC-3&#8242;</named-content>
###xml 1501 1506 1473 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
###xml 1523 1526 1489 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S14</italic>
###xml 1567 1572 1527 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UBP43</italic>
###xml 1586 1589 1546 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S14</italic>
###xml 191 194 <span type="species:ncbi:7460">Bee</span>
For analysis of IFN-induced RNA levels, cells were treated with hu-IFN-alpha-A (PBL Biomedical Laboratories) as described in the text. Total cellular RNA was isolated from 107 cells with RNA-Bee as recommended by the manufacturer (Tel-Test), followed by extraction with an equal volume of phenol-chloroform and then chloroform prior to ethanol precipitation. For RNA (northern) blot hybridization, 10 microg of RNA was fractionated by electrophoresis in a 1.2% agarose-2.2 M formaldehyde gel, followed by transfer to a GeneScreen Plus membrane (PerkinElmer Life Sciences, Inc.). RNA blots were subjected to hybridization to 32P-labeled (by nick translation) DNA probes, washed, processed by autoradiography and quantified by PhosphorImage analysis (Molecular Dynamics). Blots were stripped and rehybridized to a probe specific for 28S rRNA to control for differences in RNA loading. For analysis of UBP43 mRNA levels by reverse transcription (RT)-PCR, 2.5 microg of total RNA isolated from untreated or IFN-alpha-treated cells was reverse-transcribed using the iScript cDNA synthesis kit (BioRad). Control reactions lacking reverse transcriptase were run in parallel. One-tenth of each cDNA reaction was then amplified using either UBP43- or ribosomal protein gene S14-specific primers: UBP43, 5'-AGCAAGGCGTTTGGGCTCCTG-3' and 5'-GATCCTCGAGTAGAAGACTCCGTAGATCCAG-3'; S14, 5'-GGCAGACCGAGATGAATCCTCA-3' and 5'-CAGGTCCAGGGGTCTTGGTCC-3'. Amplification was for 25 cycles at 95degreesC for 2 min, 58degreesC (UBP43) or 55degreesC (S14) for 1 min, and 72degreesC for 2.5 min (UBP43) or 1.5 min (S14); after the final cycle of amplification, samples were maintained at 72degreesC for 5 min. Following amplification, one-tenth of each product was electrophoresed in a 1.5% agarose gel, transferred to GeneScreen Plus membrane and processed by standard Southern blot hybridization techniques to detect UBP43 cDNA.
###end p 47
###begin title 48
DNA Transfection and Reporter Assay
###end title 48
###begin p 49
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Sample1">[39]</xref>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 313 318 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 393 419 389 415 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGGCATGCCTCGGGAAAGGG-3&#8242;</named-content>
###xml 432 458 428 454 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGCACGAGCTCCTGTACTGG-3&#8242;</named-content>
###xml 514 517 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bam</italic>
###xml 324 329 <span type="species:ncbi:9606">human</span>
###xml 532 537 <span type="species:ncbi:9606">human</span>
Cells were maintained in roller bottle cultures for at least two feedings prior to transfection by electroporation, as previously described [39]. Briefly, 8x106 cells were transfected in triplicate with 10 microg of pISG15-hGH reporter plasmid. pISG15-hGH was created by PCR amplification of bases -125 to +50 of ISG15 from human genomic DNA (Promega) utilizing the following primers: ISG15a: 5'-GGGCATGCCTCGGGAAAGGG-3' and ISG15b: 5'-GGCACGAGCTCCTGTACTGG-3'. The resulting fragment was blunt-end ligated into the BamHI site of the human growth hormone (hGH) reporter plasmid pPhiGH (Nichols Institute). At 14 h post-transfection, hu-IFN-alpha-A (PBL Biomedical Laboratories) was added to cell cultures to a final concentration of 100 U/ml. The level of hGH in the culture medium was determined by radioimmunoassay (Nichols Institute) in duplicate at various intervals following addition of IFN-alpha.
###end p 49
###begin title 50
Electrophoretic Mobility Shift Assay (EMSA)
###end title 50
###begin p 51
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 579 583 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Scholer1">[40]</xref>
###xml 703 708 677 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 853 888 827 862 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GATCCTCGGGAAAGGGAAACCGAAACTGA-3&#8242;</named-content>
###xml 1003 1005 969 971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1362 1364 1316 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1309 1315 <span type="species:ncbi:9913">bovine</span>
For preparation of whole-cell extracts, 2x107 cells either untreated or treated with IFN-alpha (100 U/ml) for 4, 8, or 24 h were washed in phosphate-buffered saline (PBS) and resuspended in 200 microl extraction buffer (20 mM HEPES-KOH [pH 7.9], 450 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 25% glycerol, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 50 mM sodium fluoride, 10 mM beta-glycerophosphate, and Completetrade mark protease inhibitor cocktail [Roche]). Lysates were gently sonicated on ice and clarified by centrifugation at 12,000x g for 5 min at 4degreesC [40]. Protein concentration of the supernatant was determined by the Bradford method (BioRad). A dsDNA probe containing the ISG15 IFN-stimulated response element (ISRE) was generated from annealed complementary oligonucleotides containing 4-base 5' overhangs (sense strand: 5'-GATCCTCGGGAAAGGGAAACCGAAACTGA-3') by labeling with Klenow DNA polymerase in the presence of 1 mM each of dGTP, dTTP, dATP and 100 microCi of [alpha32P]dCTP (3,000 Ci/mmol). Unincorporated nucleotides were removed by passage through Micro Bio-Spin 6 chromatography columns (BioRad). Binding reactions were performed in a 25-microl reaction containing 10 mM HEPES-KOH (pH 7.5), 50 mM KCL, 1 mM EDTA, 0.1 mM DTT, 0.1% Triton X-100, 2.5% glycerol, 2 microg bovine serum albumin and 2 microg salmon testes DNA. 32P-labeled oligonucleotide probe (0.5 ng) was added to each binding mixture, and then incubated for 20 min at room temperature. Protein-DNA complexes were resolved by electrophoresis in non-denaturing 5% acrylamide gels run at 4degreesC in 0.5x TBE (1x TBE is 90 mM Tris, 88 mM boric acid and 2 mM EDTA). Following electrophoresis, gels were dried and processed by autoradiography.
###end p 51
###begin title 52
Immunoblotting
###end title 52
###begin p 53
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 1686 1690 1661 1665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006023-Abramoff1">[41]</xref>
###xml 1095 1106 <span type="species:ncbi:3704">horseradish</span>
###xml 1179 1184 <span type="species:ncbi:10090">mouse</span>
###xml 1312 1318 <span type="species:ncbi:9986">rabbit</span>
Cells (107) were washed once in PBS and lysed in 200 sl of lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 50 mM sodium fluoride, 10 mM beta-glycerophosphate, and Completetrade mark protease inhibitor cocktail [Roche]) by incubation on ice for 10 min. Insoluble material was removed by centrifugation at 12,000x g for 10 min, and protein concentration of the supernatant determined by the Bradford method (BioRad). Fifty micrograms of protein was fractionated by SDS-PAGE, transferred to an Immobilon P membrane (Millipore), and immunoblotted using an enhanced chemiluminescence detection system (Amersham). For detection of STAT1 and STAT2 phosphorylation, blots were initially probed with a phosphorylation site-specific antibody, subsequently stripped of antibody in 62.5 mM Tris-HCl (pH 6.8), 100 mM 2-mercaptoethanol and 2% SDS (50degreesC for 30 min) and re-probed with a phosphorylation-state independent antibody. Immunoreactive proteins were detected with secondary antibodies conjugated to horseradish peroxidase. Blots were then stripped a second time and re-probed with a mouse monoclonal antibody to beta-actin (Amersham) as a control for protein loading. Primary antibodies used for immunoblotting were rabbit polyclonal antisera to STAT1 p84/p91 (Santa Cruz Biotechnology), phospho-STAT1 (Tyr701 and Ser727; Upstate Biotechnology), STAT2 (Santa Cruz Biotechnology), phospho-STAT2 (Tyr689; Upstate Biotechnology), and IRF9/ISGF-3gamma/p48 (Santa Cruz Biotechnology). Detection of FLAG-UBP43 was with anti-FLAG antibody (M2; Sigma). Signal intensity was quantified using ImageJ [41].
###end p 53
###begin title 54
Supporting Information
###end title 54
###begin p 55
###xml 369 376 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g004">Figs. 4</xref>
###xml 381 382 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006023-g005">5</xref>
###xml 64 67 <span type="species:ncbi:10376">EBV</span>
###xml 80 83 <span type="species:ncbi:10376">EBV</span>
###xml 177 180 <span type="species:ncbi:10376">EBV</span>
###xml 209 212 <span type="species:ncbi:10376">EBV</span>
Duration of tyrosine phosphorylation of STAT1 is independent of EBV status. Two EBV-positive BL cell lines (KemI and MutuI) as well as two independently derived matched sets of EBV-negative (Ak- and 2A8-) and EBV-positive (Ak+ and 2A8+) Akata BL cells were treated with IFN-alpha for up to 24 h. Tyrosine phosphorylation of STAT1 was monitored by immunoblotting, as in Figs. 4 and 5. The faster-migrating background band (asterisk) served as protein loading controls on all blots.
###end p 55
###begin p 56
(0.55 MB TIF)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
We thank Drs. John W. Sixbey (Louisiana State University Health Science Center) and Kenzo Takada (Hokkaido University School of Medicine, Sapporo, Japan) for cell lines, and E.B. Daniel Henson and Christopher Davis for excellent technical assistance.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
Translocations involving c-myc and c-myc function.
###end article-title 60
###begin article-title 61
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed.
###end article-title 61
###begin article-title 62
Epstein-Barr Virus and Its Replication.
###end article-title 62
###begin article-title 63
Identification of Virus-Encoded MicroRNAs.
###end article-title 63
###begin article-title 64
The curious case of the tumour virus: 50 years of Burkitt's lymphoma.
###end article-title 64
###begin article-title 65
###xml 40 58 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
###end article-title 65
###begin article-title 66
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.
###end article-title 66
###begin article-title 67
Protection from Interferon-Induced Apoptosis by Epstein-Barr Virus Small RNAs Is Not Mediated by Inhibition of PKR.
###end article-title 67
###begin article-title 68
EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN.
###end article-title 68
###begin article-title 69
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.
###end article-title 69
###begin article-title 70
UBP43 (USP18) specifically removes ISG15 from conjugated proteins.
###end article-title 70
###begin article-title 71
Protein ISGylation modulates the JAK-STAT signaling pathway.
###end article-title 71
###begin article-title 72
UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity.
###end article-title 72
###begin article-title 73
###xml 13 31 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 33 36 <span type="species:ncbi:10376">EBV</span>
###xml 68 71 <span type="species:ncbi:10376">EBV</span>
###xml 167 170 <span type="species:ncbi:10376">EBV</span>
Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.
###end article-title 73
###begin article-title 74
###xml 18 36 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata.
###end article-title 74
###begin article-title 75
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata.
###end article-title 75
###begin article-title 76
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.
###end article-title 76
###begin article-title 77
Epstein-barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma.
###end article-title 77
###begin article-title 78
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
###end article-title 78
###begin article-title 79
Negative regulation of cytokine signaling pathways.
###end article-title 79
###begin article-title 80
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
###end article-title 80
###begin article-title 81
Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.
###end article-title 81
###begin article-title 82
SOCS proteins: negative regulators of cytokine signaling.
###end article-title 82
###begin article-title 83
###xml 76 93 <span type="species:ncbi:11103">hepatitis C virus</span>
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection.
###end article-title 83
###begin article-title 84
The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins.
###end article-title 84
###begin article-title 85
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling.
###end article-title 85
###begin article-title 86
###xml 95 99 <span type="species:ncbi:10090">mice</span>
Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice.
###end article-title 86
###begin article-title 87
###xml 140 174 <span type="species:ncbi:11623">lymphocytic choriomeningitis virus</span>
ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus.
###end article-title 87
###begin article-title 88
###xml 32 37 <span type="species:ncbi:9606">human</span>
###xml 102 107 <span type="species:ncbi:9606">human</span>
Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH.
###end article-title 88
###begin article-title 89
Involvement of proteasomes in gene induction by interferon and double-stranded RNA.
###end article-title 89
###begin article-title 90
###xml 52 56 <span type="species:ncbi:10090">mice</span>
###xml 65 87 <span type="species:ncbi:90371">Salmonella typhimurium</span>
Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling.
###end article-title 90
###begin article-title 91
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection.
###end article-title 91
###begin article-title 92
###xml 100 104 <span type="species:ncbi:10090">mice</span>
A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation.
###end article-title 92
###begin article-title 93
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 90 96 <span type="species:ncbi:10090">murine</span>
Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18).
###end article-title 93
###begin article-title 94
Ubp43 gene expression is required for normal Isg15 expression and fetal development.
###end article-title 94
###begin article-title 95
Dysregulation of protein modification by ISG15 results in brain cell injury.
###end article-title 95
###begin article-title 96
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.
###end article-title 96
###begin article-title 97
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 90 95 <span type="species:ncbi:9606">human</span>
Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling.
###end article-title 97
###begin article-title 98
###xml 4 22 <span type="species:ncbi:10376">Epstein-Barr virus</span>
The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
###end article-title 98
###begin article-title 99
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor.
###end article-title 99
###begin article-title 100
Image Processing with ImageJ.
###end article-title 100
###begin p 101
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 101
###begin p 102
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
###xml 45 53 <span type="species:ncbi:9606">Children</span>
Funding: This work was initiated at St. Jude Children's Research Hospital (SJCRH), Memphis, TN, 38105, and was supported by U.S. Public Health Service (PHS) grants CA056639 and CA073544 (to J.T.S.) and Cancer Center Support Grants CA21765 (to SJCRH) and CA62203 (to UCI) from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities (ALSAC) and the Penn State Hershey Cancer Institute. J.L.H. was supported in part by PHS grant T32-AI007319. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 102

